Univariable logistic regression analysis of factors associated with ORR
| Variable . | Level . | n . | Odds ratio (95% CI) . | P value . |
|---|---|---|---|---|
| MIPI score at diagnosis | High risk | 24 | 0.70 (0.23-2.17) | .536 |
| Low/intermediate risk | 26 | — | ||
| TP53 alterations at diagnosis | Yes | 16 | 0.56 (0.12-2.54) | .448 |
| No | 16 | — | — | |
| MIPI score before venetoclax | High risk | 26 | 0.94 (0.32-2.75) | .906 |
| Low/intermediate risk | 30 | |||
| TP53 alterations before venetoclax | Yes | 7 | 0.57 (0.09-3.83) | .564 |
| No | 17 | — | — | |
| Blastoid/pleomorphic histology before venetoclax | Yes | 24 | 1.11 (0.38-3.26) | .854 |
| No | 30 | — | — | |
| Complex karyotype before venetoclax | Yes | 6 | 1.25 (0.20-7.96) | .813 |
| No | 18 | — | — | |
| No. of lines of treatment before venetoclax | >3 | 20 | 0.26 (0.08-0.90) | .033 |
| ≤3 | 47 | — | — | |
| POD24 | Yes | 32 | 1.30 (0.48-3.52) | .611 |
| No | 32 | — | ||
| Best response to last therapy before venetoclax | CR, PR | 28 | 2.27 (0.81-6.34) | .117 |
| SD, PD | 36 | — | — | |
| Duration of treatment with last therapy before venetoclax, mo | >4 | 30 | 2.27 (0.83-6.22) | .110 |
| ≤4 | 36 | — | — | |
| Best response to BTKi | CR, PR | 35 | 2.39 (0.76-7.49) | .136 |
| SD, PD | 23 | — | — | |
| Duration of treatment with BTKi, mo | >6 | 31 | 1.96 (0.66-5.80) | .227 |
| ≤6 | 27 | — | — | |
| Reason for stopping BTKi | PD | 51 | 0.73 (0.15-3.61) | .697 |
| Toxicity | 7 | — | — | |
| Venetoclax combined with other agent(s) | Combination | 29 | 1.79 (0.67-4.83) | .247 |
| Monotherapy | 38 | — | — | |
| Venetoclax highest dose received, mg | ≥400 | 53 | 1.65 (0.42-6.42) | .47 |
| <400 | 10 | — | — | |
| Venetoclax highest dose received, mg | 800 | 12 | 0.78 (0.2-3.03) | .72 |
| 400 | 41 | — | — |
| Variable . | Level . | n . | Odds ratio (95% CI) . | P value . |
|---|---|---|---|---|
| MIPI score at diagnosis | High risk | 24 | 0.70 (0.23-2.17) | .536 |
| Low/intermediate risk | 26 | — | ||
| TP53 alterations at diagnosis | Yes | 16 | 0.56 (0.12-2.54) | .448 |
| No | 16 | — | — | |
| MIPI score before venetoclax | High risk | 26 | 0.94 (0.32-2.75) | .906 |
| Low/intermediate risk | 30 | |||
| TP53 alterations before venetoclax | Yes | 7 | 0.57 (0.09-3.83) | .564 |
| No | 17 | — | — | |
| Blastoid/pleomorphic histology before venetoclax | Yes | 24 | 1.11 (0.38-3.26) | .854 |
| No | 30 | — | — | |
| Complex karyotype before venetoclax | Yes | 6 | 1.25 (0.20-7.96) | .813 |
| No | 18 | — | — | |
| No. of lines of treatment before venetoclax | >3 | 20 | 0.26 (0.08-0.90) | .033 |
| ≤3 | 47 | — | — | |
| POD24 | Yes | 32 | 1.30 (0.48-3.52) | .611 |
| No | 32 | — | ||
| Best response to last therapy before venetoclax | CR, PR | 28 | 2.27 (0.81-6.34) | .117 |
| SD, PD | 36 | — | — | |
| Duration of treatment with last therapy before venetoclax, mo | >4 | 30 | 2.27 (0.83-6.22) | .110 |
| ≤4 | 36 | — | — | |
| Best response to BTKi | CR, PR | 35 | 2.39 (0.76-7.49) | .136 |
| SD, PD | 23 | — | — | |
| Duration of treatment with BTKi, mo | >6 | 31 | 1.96 (0.66-5.80) | .227 |
| ≤6 | 27 | — | — | |
| Reason for stopping BTKi | PD | 51 | 0.73 (0.15-3.61) | .697 |
| Toxicity | 7 | — | — | |
| Venetoclax combined with other agent(s) | Combination | 29 | 1.79 (0.67-4.83) | .247 |
| Monotherapy | 38 | — | — | |
| Venetoclax highest dose received, mg | ≥400 | 53 | 1.65 (0.42-6.42) | .47 |
| <400 | 10 | — | — | |
| Venetoclax highest dose received, mg | 800 | 12 | 0.78 (0.2-3.03) | .72 |
| 400 | 41 | — | — |